

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(Not for submission under 37 CFR 1.99)</small>	Application Number	10568255
	Filing Date	2008-02-13
	First Named Inventor	ZHANQI LIU, et al.
	Art Unit	
	Examiner Name	
	Attorney Docket Number	040000-0360741

U.S.PATENTS						
Examiner Initial ¹	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS						
Examiner Initial ¹	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS							
Examiner Initial ¹	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1						

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS							
Examiner Initials ¹	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.					T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10568255
Filing Date	2006-02-13
First Named Inventor	ZHANQI LIU, et al.
Art Unit	
Examiner Name	
Attorney Docket Number	040000-0360741

1	Bhattacharya-Chatterjee, M. , S. K. Chatterjee, et al. (2001). "The anti-idiotype vaccines for immunotherapy. "Curr Opin Mol Ther 3 (1) : 63-9.	<input type="checkbox"/>
2	Brown, G. and N. Ling (1988). Murine Monoclonal Antibodies. Antibodies. Volume 1. A Practical Approach. D. Catty. Oxford, England, RL Press: 81-104.	<input type="checkbox"/>
3	Clark, M. (2000). "Antibody humanization: a case of the'Emperor's new clothes'?" Immunol Today 21 (8): 397-402.	<input type="checkbox"/>
4	Clarke, K. , F. T. Lee, et al. (2000a). "In vivo biodistribution of a humanized anti-Lewis Y monoclonal antibody (hu3S193) in MCF-7 xenografted BALB/c nude mice." Cancer Res 60 (17): 4804-11.	<input type="checkbox"/>
5	Clarke, K. , F. T. Lee, et al. (2000b). "Therapeutic efficacy of anti-Lewis (y) humanized 3S193 radioimmunotherapy in a breast cancer model : enhanced activity when combined with taxol chemotherapy." Clin Cancer Res 6 (9): 3621-8.	<input type="checkbox"/>
6	Fields, B. A. , F. A. Goldbaum, et al. (1995). "Molecular basis of antigen mimicry by an anti-idiotope. " Nature 374 (6524): 739-42.	<input type="checkbox"/>
7	Glennie, M. J. and P. W. Johnson (2000). "Clinical trials of antibody therapy." Immunol Today 21 (8) : 403-10.	<input type="checkbox"/>
8	Gruber, R. , L. J. van Haarlem, et al. (2000). "The human antimouse immunoglobulin response and the anti-idiotypic network have no influence on clinical outcome in patients with minimal residual colorectal cancer treated with monoclonal antibody C017-1A." Cancer Res 60 (7): 1921-6.	<input type="checkbox"/>
9	Hoffman, E. W. , A. M. Scott, et al. (2001). Phase I trials of CDR-grafted humanized monoclonal antibody hu3S193 in patients with Lewis-Y expressing solid tumors ASCO 37th Annual Meeting, San Francisco.	<input type="checkbox"/>
10	Jerne, N. K. (1974). "Towards a network theory of the immune system." Ann Immunol (Paris) 125C (1-2) : 373-89.	<input type="checkbox"/>
11	Kim, Y. S. , M. Yuan, et al. (1986). "Expression of LeY and extended LeY blood group- related antigens in human malignant, premalignant, and nonmalignant colonic tissues. " Cancer Res 46 (11): 5985-92.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10568255
Filing Date	2006-02-13
First Named Inventor	ZHANQI LIU, et al.
Art Unit	
Examiner Name	
Attorney Docket Number	040000-0360741

12	Kitamura, K. , E. Stockert, et al. (1994). "Specificity analysis of blood group Lewis-y (Le (y)) antibodies generatedagainst synthetic and natural Le (y) determinants." Proc Natl Acad Sci U S A 91 (26) : 12957-61.	<input type="checkbox"/>
13	Liu, Z. , F. E. Smyth, et al. (2002)."Anti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity." Cancer Immunol Immunother 51 (3): 171-7.	<input type="checkbox"/>
14	Ritter, G. , L. S. Cohen, et al. (2001)."Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33."Cancer Res 61 (18): 6851-9.	<input type="checkbox"/>
15	Safa, M. M. and K. A. Foon (2001)."Adjuvant immunotherapy for melanoma and colorectal cancers." Semin Oncol 28 (1) : 68-92.	<input type="checkbox"/>
16	Sakamoto, J. , K. Furukawa, et al. (1986). "Expression of Lewisa, Lewisb, X, and Y blood group antigens in human colonic tumors and normal tissue and in human tumor- derived cell lines."Cancer Res 46 (3): 1553-61.	<input type="checkbox"/>
17	Scott, A. M. , D. Geleick, et al. (2000). "Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors."Cancer Res 60 (12): 3254-61.	<input type="checkbox"/>
18	Steffens, M. G., O. C. Boerman, et al. (1997). "Targeting of renal cell carcinoma with Iodine-131-labeled chimeric monoclonal antibody G250."J Clin Oncol 15 (4): 1529-37.	<input type="checkbox"/>
19	Uemura, H. , E. Okajima, et al. (1994)."Internal image anti-idiotype antibodies related to renal-cell carcinoma-associated antigen G250."Int J Cancer 56 (4): 609-14.	<input type="checkbox"/>
20	Zhang, S. , C. Cordon-Cardo, et al. (1997)."Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides."Int J Cancer 73 (1) : 42-9.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.